Amplia TherapeuticsASX:ATX 36 Market Cap is A$69.30 Mil as of Jun. 26, 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, Amplia Therapeutics ranks worse than 63.52% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amplia Therapeutics's share price for the quarter that ended in Mar. 2026 was A$0.235. Amplia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 513.07 Mil. Therefore, Amplia Therapeutics's market cap for the quarter that ended in Mar. 2026 was A$120.57 Mil.
Amplia Therapeutics's quarterly market cap
increased
from Mar. 2025 (A$27.16 Mil) to Sep. 2025 (A$76.96 Mil) and
increased
from Sep. 2025 (A$76.96 Mil) to Mar. 2026 (A$120.57 Mil).
Amplia Therapeutics's annual market cap
increased
from Mar. 2024 (A$14.94 Mil) to Mar. 2025 (A$27.16 Mil) and
increased
from Mar. 2025 (A$27.16 Mil) to Mar. 2026 (A$120.57 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amplia Therapeutics's Enterprise Value for Today is A$41.78 Mil.
Amplia Therapeutics (ASX:ATX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amplia Therapeutics Market Cap Related Terms
Amplia Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Amplia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ATX vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Amplia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amplia Therapeutics's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (ASX:ATX) has a Market Cap of A$69.30 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amplia Therapeutics and its competitors. According to the industry distribution chart, Amplia Therapeutics ranks #909 out of 1431 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Amplia Therapeutics' Market Cap too high?
Amplia Therapeutics' current Market Cap is A$69.30 Mil. Based on the distribution chart, Amplia Therapeutics ranks #909 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #909 out of 1431 companies for Market Cap. This places Amplia Therapeutics in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amplia Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current Market Cap is A$69.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Market Cap of A$69.30 Mil. The current Market Cap is A$69.30 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Market Cap is A$69.30 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score
Get the complete analysis for ASX:ATX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
